Evidence map›Paper›PMID 38183002›Full record

ArticleBMC infectious diseases2024

Dyslipidemia among adult people living with HIV on dolutegravir - based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants.

Vianney John Kigongo, Joaniter I Nankabirwa, Freddy Eric Kitutu, Ronald Ssenyonga, Ronald Kasoma Mutebi, Andrew Kazibwe, Ronald Kiguba, Andrew D Kambugu, Barbara Castelnuovo

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Vianney John KigongoClinical Epidemiology Unit, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. joviaky@gmail.com.
Joaniter I NankabirwaClinical Epidemiology Unit, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Freddy Eric KitutuDepartment of Pharmacy, Makerere University School of Health Sciences, Kampala, Uganda.
Ronald SsenyongaDepartment of Epidemiology and Biostatistics, Makerere University School of Public Health, Kampala, Uganda.
Ronald Kasoma MutebiDepartment of Medicine, Mengo Hospital, Kampala, Uganda.
Andrew KazibweThe AIDS Support Organisation (TASO), Kampala, Uganda.
Ronald KigubaDepartment of Pharmacology and Therapeutics, Makerere University College of Health Sciences, Kampala, Uganda.
Andrew D KambuguInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Barbara CastelnuovoInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Makerere University · UGInfectious Diseases Institute · UGThe AIDS Support Organization · UGMengo Hospital · UG

Funding

HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
FIC NIH HHS D43 TW009771Medical Research Council MR/V03510X/1
6 · The paper itself

Abstract

backgroundUnderstanding the burden of dyslipidemia and its associated factors among adult people living with HIV on dolutegravir (DTG) based anti-retroviral therapy (ART) is critical to provide clinical guidance and risk reduction strategies in our setting.

methodsWe conducted a cross-sectional study on adult people living with HIV on DTG based ART between July and August 2022 at Mengo Hospital, a private not for profit missionary hospital owned by the Church of Uganda. Dyslipidemia was defined as: Total cholesterol (TC) ≥ 5.2 mmol/l, or high-density lipoprotein (HDL) < 1 mmol/l for men and < 1.3 mmol/l for women, or triglycerides (TG) ≥ 1.7 mmol/l, and low-density lipoprotein (LDL) ≥ 3.4 mmol/l. A participant was considered to have dyslipidemia if they had any of the lipid profile parameters in the above ranges. Socio-demographic information, clinical data and behavioral characteristics were collected. Fasting lipid profile and fasting blood glucose levels were also measured. Bivariate and multivariate analyses were done using a generalized linear model regression of the Poisson family with a log link (modified Poisson) using robust standard errors since the prevalence of dyslipidemia was more than 10%. Adjusted prevalence ratios (PR) were reported with their 95% confidence intervals (CI). A p-value of less than 0.05 was considered statistically significant.

resultsA total of 341 participants were included. The prevalence of dyslipidemia was 78.0%, (95%CI:73.3-82.1). The highest prevalence was for low HDL (72.1%, 95%CI 67.1-76.7) followed by high TG (20.2%, 95%CI: 16.3-24.9), high TC (12.0%, 95%CI: 9.0-15.9) and high LDL (6.5%, 95%CI: 4.3-9.6). Female sex (aPR:1.55, 95%CI: 1.32-1.84, p < 0.001) and previous use of protease inhibitor (PI) based ART regimen (aPR:1.26, 95%CI: 1.04-1.53, p = 0.018) were significantly associated with dyslipidemia.

conclusionWe demonstrate that the prevalence of dyslipidemia is very high as it was present in more than three quarters of the study participants. Female sex and previous use of PI based ART regimen were significantly associated with dyslipidemia. Management of dyslipidemia should be integrated in the HIV treatment package and we recommend further inquiry into the temporal relationship between dyslipidemia and DTG among ART patients, if any.

Indexed as

DyslipidemiasAdultCross-Sectional StudiesDolutegravirFemaleHumansLipoproteins, LDLMaleTertiary Care CentersUgandaDolutegravirLipoproteins, LDLAntiretroviral therapy (ART)Dolutegravir (DTG)DyslipidemiaHigh density lipoprotein (HDL)HIV/AIDSLow density lipoprotein (LDL)Total cholesterol (TC)Triglycerides (TG)Uganda

Identifiers

PMID38183002
PMCPMC10770888
OpenAlexW4390617759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.